Connaughton Bernadette has amended her previous SEC filing regarding her restricted stock unit (RSU) grant. This amendment corrects the number of shares acquired, which is important for transparency in executive compensation.

Halozyme Therapeutics, where Bernadette serves as a director, is a company focused on biological products. The firm is listed under the SIC code for Biological Products (No Diagnostic Substances) [2836]. The recent filing was made on October 8, 2026, and is part of a series of disclosures that highlight corporate governance practices.

The filing states, "This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction." The corrected number of RSUs acquired is 3,796, down from the previously reported 6,796. Following this transaction, Bernadette owns a total of 42,294 shares.

This update may affect shareholders and stakeholders who are interested in the ownership structure and compensation of directors at Halozyme. The correction reflects the company's commitment to accurate reporting and transparency.

The filing does not say what happens next.

Details of the RSU Grant

The amended filing indicates that the RSUs granted to Connaughton Bernadette are part of the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of Halozyme Therapeutics. Notably, this grant is set to vest in full on the earlier of May 5, 2027, or the date of the Issuer's next annual meeting of stockholders.

Ownership Structure

Following the acquisition of the corrected number of RSUs, Bernadette now holds a total of 42,294 shares of common stock in Halozyme Therapeutics. This adjustment in ownership is significant as it reflects the changes in the executive compensation structure and the overall ownership distribution within the company.

"This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction."

Furthermore, the filing does not provide any information regarding future transactions or potential changes in Bernadette's holdings.